ClinicalTrials.gg
CompletedNCT02098395ADJUNCT TWO™Updated Feb 9, 2017Results posted

The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes

A Phase 3 interventional study of liraglutide and liraglutide in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 120 sites in 13 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-02-09.

Primary conditionDiabetes Mellitus, Type 1Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 1
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 1, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
835
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing liraglutide in Diabetes Mellitus, Type 1 — 2 open to participants now, 2 under way, none of them phase 3. Liraglutide · Diabetes Mellitus, Type 1.

Enrollment
2nd of 32
835 · median 38
Started
2014
with 2 others
Phase 3
9 of 32
none open now
Registered
15th of 32
by date
Lead sponsor
5 of 32
Novo Nordisk A/S

Among the 32 studies testing liraglutide in Diabetes Mellitus, Type 1, this one is the 2nd largest by enrollment, is one of 3 that started in 2014, is one of 9 in phase 3, and was the 15th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 32 studies testing liraglutide in Diabetes Mellitus, Type 1 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing liraglutide in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

This trial is conducted in Africa, Europe and North America. The purpose of the trial is to investigate the efficacy and safety of liraglutide adjunct to insulin treatment in type 1 diabetes.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 1

Browse trials for

04

In context

Diabetes Mellitus, Type 1 Reclassified

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's enrollment of 835 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
  • Male or female, aged equal to or greater than 18 years at the time of signing informed consent
  • Type 1 diabetes mellitus (as diagnosed clinically) 12 months or longer prior to Visit 1 (i.e. screening)
  • Treatment with basal bolus or CSII (continuous subcutaneous insulin infusion, insulin pump) treatment 6 months or longer prior to Visit 1 (i.e. screening)
  • Stable insulin treatment 3 months or longer prior to Visit 1 (i.e. screening), as judged and documented by the investigator
  • 7.0-10.0 percent (Diabetes Control and Complications Trial (DCCT)), both inclusive, by central laboratory analysis (Visit 1, screening) corresponding to 53-86 mmol/mol (International Federation of Clinical Chemistry (IFCC))

Exclusion criteria

Exclusion Criteria:

  • Prior use of glucagon-like peptide-1 (GLP-1) receptor agonist or dipeptidyl peptidase IV (DPPIV) inhibitors
  • Use of any medication, which in the investigator's opinion could interfere with the glycaemic control (e.g. systemic , pramlintide (Symlin®)) or affect the subject's safety. Premix insulin is not allowed
  • Known proliferative retinopathy or maculopathy requiring acute treatment
  • Severe neuropathy, in particular autonomic neuropathy, i.e. gastroparesis, as judged by the investigator
  • Uncontrolled/untreated blood pressure at screening (Visit 1) (after resting for 5 minutes) while sitting greater than 160 mmHg for systolic or greater than 100 mmHg for diastolic (repeated measurement at Visit 2 (prior to performing the trial related activities) is allowed to exclude white-coat hypertension)
  • History of acute or chronic pancreatitis
  • Screening (Visit 1) calcitonin value equal to or greater than 50 ng/L
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
835 participants (actual)

Study arms

  • Experimental
    Liraglutide 1.8 mg + insulin

    Drug: liraglutide

  • Experimental
    Liraglutide 1.2 mg + insulin

    Drug: liraglutide

  • Experimental
    Liraglutide 0.6 mg + insulin

    Drug: liraglutide

  • Placebo comparator
    Liraglutide placebo 0.3 ml + insulin

    Drug: placebo

  • Placebo comparator
    Liraglutide placebo 0.2 ml + insulin

    Drug: placebo

  • Placebo comparator
    Liraglutide placebo 0.1 ml + insulin

    Drug: placebo

Interventions

  • Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.

  • Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.

  • Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.

  • Drugplacebo

    Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.

  • Drugplacebo

    Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.

  • Drugplacebo

    Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.

07

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycosylated Haemoglobin (HbA1c)

    Change from baseline in glycosylated haemoglobin (HbA1c), after 26 weeks of treatment. Full analysis set (FAS = 831) included all randomised subjects who had received at least one dose and had any post-randomisation data.

    Time frame: Week 0, Week 26

Secondary outcomes

  1. Change From Baseline in Body Weight

    Change from baseline body weight, after 26 weeks of treatment. Full analysis set (FAS = 831) included all randomised subjects who had received at least one dose and had any post-randomisation data.

    Time frame: Week 0, Week 26

  2. Number of Treatment-emergent Symptomatic Hypoglycaemic Episodes

    Number of treatment-emergent symptomatic hypoglycaemic episodes during 26 weeks of treatment. Symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or a self-measured plasma glucose (SMPG) value of \<3.1 mmol/L (56 mg/dL), with symptoms consistent with hypoglycaemia. Severe hypoglycaemia as per ADA classification is defined as an episode that required assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions.

    Time frame: Weeks 0-26

08

Results

Posted Jun 3, 2016

Participant flow

Subjects were randomised at 113 sites in 13 countries: Austria 2 sites, Belgium 9 sites, Bulgaria 5 sites, Canada 9 sites, Denmark 4 sites, Finland 6 sites, France 9 sites, Italy 7 sites, Netherlands 5 sites, South Africa 2 sites, Spain 5 sites, Sweden 5 sites, United States 45 sites.

Participant flow — Overall Study
MilestoneLiraglutide 0.6 mgLiraglutide 1.2 mgLiraglutide 1.8 mgLiraglutide Placebo
Started212209207207
Exposed211209206206
Completed186177165180
Not completed26324227
Withdrew: Protocol violation2207
Withdrew: Withdrawal by subject1010513
Withdrew: Adverse event1219342
Withdrew: Lost to follow-up2103
Withdrew: Unclassified0032

Outcome measures

PrimaryChange From Baseline in Glycosylated Haemoglobin (HbA1c)

Change from baseline in glycosylated haemoglobin (HbA1c), after 26 weeks of treatment. Full analysis set (FAS = 831) included all randomised subjects who had received at least one dose and had any post-randomisation data.

Time frame:
Week 0, Week 26
Reported as:
Mean · Percent (%) glycosylated haemoglobin
Change From Baseline in Glycosylated Haemoglobin (HbA1c)
Percent (%) glycosylated haemoglobinLiraglutide 0.6 mgLiraglutide 1.2 mgLiraglutide 1.8 mgLiraglutide Placebo
Change From Baseline in Glycosylated Haemoglobin (HbA1c)-0.23 ± 0.744-0.23 ± 0.731-0.32 ± 0.730.01 ± 0.674
Statistical analysis
  • Liraglutide 1.8 mg vs Liraglutide Placebo · Mixed Models Analysis · p = < 0.0001 · Mean difference (final values): -0.35 · 95% CI -0.5 to -0.2
  • Liraglutide 1.2 mg vs Liraglutide Placebo · Mixed Models Analysis · p = = 0.0021 · Mean difference (final values): -0.23 · 95% CI -0.38 to -0.08
  • Liraglutide 0.6 mg vs Liraglutide Placebo · Mixed Models Analysis · p = = 0.0011 · Mean difference (final values): -0.24 · 95% CI -0.39 to -0.1
SecondaryChange From Baseline in Body Weight

Change from baseline body weight, after 26 weeks of treatment. Full analysis set (FAS = 831) included all randomised subjects who had received at least one dose and had any post-randomisation data.

Time frame:
Week 0, Week 26
Reported as:
Mean · kg
Change From Baseline in Body Weight
kgLiraglutide 0.6 mgLiraglutide 1.2 mgLiraglutide 1.8 mgLiraglutide Placebo
Change From Baseline in Body Weight-2.37 ± 3.015-4.03 ± 3.677-5.1 ± 3.787-0.26 ± 2.782
SecondaryNumber of Treatment-emergent Symptomatic Hypoglycaemic Episodes

Number of treatment-emergent symptomatic hypoglycaemic episodes during 26 weeks of treatment. Symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or a self-measured plasma glucose (SMPG) value of \<3.1 mmol/L (56 mg/dL), with symptoms consistent with hypoglycaemia. Severe hypoglycaemia as per ADA classification is defined as an episode that required assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions.

Time frame:
Weeks 0-26
Reported as:
Number · episodes
Number of Treatment-emergent Symptomatic Hypoglycaemic Episodes
episodesLiraglutide 0.6 mgLiraglutide 1.2 mgLiraglutide 1.8 mgLiraglutide Placebo
Number of Treatment-emergent Symptomatic Hypoglycaemic Episodes1437194314901567

Adverse events

Collected over From the first day of exposure to randomised treatment (week 0) to 7 days after the last day of randomised treatment (week 26).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Liraglutide 0.6 mg—20/211 (9.5%)137/211 (64.9%)
Liraglutide 1.2 mg—21/209 (10%)164/209 (78.5%)
Liraglutide 1.8 mg—14/206 (6.8%)162/206 (78.6%)
Liraglutide Placebo—14/206 (6.8%)125/206 (60.7%)
Most frequent serious events
Showing 10 of 54
Most frequent serious events
EventLiraglutide 0.6 mgLiraglutide 1.2 mgLiraglutide 1.8 mgLiraglutide Placebo
Hypoglycaemic unconsciousnessNervous system disorders3/2116/2092/2061/206
HypoglycaemiaMetabolism and nutrition disorders5/2112/2091/2061/206
Coronary artery diseaseCardiac disorders0/2110/2090/2062/206
HyperglycaemiaMetabolism and nutrition disorders0/2110/2092/2062/206
DiarrhoeaGastrointestinal disorders0/2112/2090/2060/206
VomitingGastrointestinal disorders0/2112/2090/2061/206
Myocardial infarctionCardiac disorders0/2110/2090/2061/206
VolvulusGastrointestinal disorders0/2110/2091/2060/206
Chest painGeneral disorders0/2110/2091/2060/206
Non-cardiac chest painGeneral disorders0/2110/2090/2061/206
Most frequent other events
Showing 10 of 18
Most frequent other events
EventLiraglutide 0.6 mgLiraglutide 1.2 mgLiraglutide 1.8 mgLiraglutide Placebo
NauseaGastrointestinal disorders68/21197/209102/20634/206
Decreased appetiteMetabolism and nutrition disorders21/21140/20950/2069/206
NasopharyngitisInfections and infestations44/21140/20947/20646/206
VomitingGastrointestinal disorders19/21129/20935/2067/206
DiarrhoeaGastrointestinal disorders14/21125/20930/20617/206
HeadacheNervous system disorders16/21126/20930/20630/206
Upper respiratory tract infectionInfections and infestations14/21111/20911/20625/206
DyspepsiaGastrointestinal disorders8/21119/20924/2061/206
ConstipationGastrointestinal disorders6/21123/20914/2069/206
FatigueGeneral disorders13/21117/20922/2063/206

Baseline characteristics

Baseline (BL) characteristics were presented for full analysis set (FAS = 831 subjects). Out of 835 randomised subjects, 4 were excluded from FAS:1 subject each in the lira 1.8 mg, 0.6 mg and placebo arm were not exposed to trial treatment and 1 subject in the lira 1.8 mg arm had no post-BL measurements.

Age, Continuous
Age, Continuous(years)Liraglutide 0.6 mgLiraglutide 1.2 mgLiraglutide 1.8 mgLiraglutide PlaceboTotal
Mean43.9 ± 12.8842.8 ± 13.3143.2 ± 12.942.7 ± 12.9743.2 ± 13.00
Gender
Gender(Participants)Liraglutide 0.6 mgLiraglutide 1.2 mgLiraglutide 1.8 mgLiraglutide PlaceboTotal
Female118106113112449
Male931039294382
Glycosylated Haemoglobin (HbA1c)
Glycosylated Haemoglobin (HbA1c)(Percent (%) glycosylated haemoglobin)Liraglutide 0.6 mgLiraglutide 1.2 mgLiraglutide 1.8 mgLiraglutide PlaceboTotal
Mean8.09 ± 0.7438.07 ± 0.7318.04 ± 0.7368.12 ± 0.7238.08 ± 0.732
Body Weight
Body Weight(kg)Liraglutide 0.6 mgLiraglutide 1.2 mgLiraglutide 1.8 mgLiraglutide PlaceboTotal
Mean83.10 ± 16.13784.69 ± 18.15583.64 ± 17.62084.20 ± 16.53983.91 ± 17.109
09

Study locations

120 sites
  • Novo Nordisk Investigational Site
    Phoenix, Arizona 85032, United States
  • Novo Nordisk Investigational Site
    Little Rock, Arkansas 72205, United States
  • Novo Nordisk Investigational Site
    Concord, California 94520, United States
  • Novo Nordisk Investigational Site
    Escondido, California 92025, United States
  • Novo Nordisk Investigational Site
    Fresno, California 93720, United States
  • Novo Nordisk Investigational Site
    Montclair, California 91763, United States
  • Novo Nordisk Investigational Site
    San Mateo, California 94401, United States
  • Novo Nordisk Investigational Site
    San Ramon, California 94583, United States
  • Novo Nordisk Investigational Site
    Ventura, California 93003, United States
  • Novo Nordisk Investigational Site
    Walnut Creek, California 94598, United States
  • Novo Nordisk Investigational Site
    Aurora, Colorado 80045, United States
  • Novo Nordisk Investigational Site
    Golden, Colorado 80401, United States
  • Novo Nordisk Investigational Site
    Maitland, Florida 32751, United States
  • Novo Nordisk Investigational Site
    Atlanta, Georgia 30318, United States
  • Novo Nordisk Investigational Site
    Marietta, Georgia 30060, United States
  • Novo Nordisk Investigational Site
    Roswell, Georgia 30076, United States
  • Novo Nordisk Investigational Site
    Champaign, Illinois 61821, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60611, United States
  • Novo Nordisk Investigational Site
    Skokie, Illinois 60077, United States
  • Novo Nordisk Investigational Site
    Council Bluffs, Iowa 51501, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40503, United States
  • Novo Nordisk Investigational Site
    Rockville, Maryland 20852, United States
  • Novo Nordisk Investigational Site
    Minneapolis, Minnesota 55416, United States
  • Novo Nordisk Investigational Site
    Chesterfield, Missouri 63017, United States
  • Novo Nordisk Investigational Site
    Billings, Montana 59101, United States
  • Novo Nordisk Investigational Site
    Butte, Montana 59701, United States
  • Novo Nordisk Investigational Site
    Las Vegas, Nevada 89128, United States
  • Novo Nordisk Investigational Site
    Albany, New York 12206, United States
  • Novo Nordisk Investigational Site
    Jamaica, New York 11432-1121, United States
  • Novo Nordisk Investigational Site
    Staten Island, New York 10301, United States
  • Novo Nordisk Investigational Site
    Chapel Hill, North Carolina 27517, United States
  • Novo Nordisk Investigational Site
    Morehead City, North Carolina 28557, United States
  • Novo Nordisk Investigational Site
    Wilmington, North Carolina 28401, United States
  • Novo Nordisk Investigational Site
    Fargo, North Dakota 58103, United States
  • Novo Nordisk Investigational Site
    Bristol, Tennessee 37620-7352, United States
  • Novo Nordisk Investigational Site
    Chattanooga, Tennessee 37411, United States
  • Novo Nordisk Investigational Site
    Amarillo, Texas 79106, United States
  • Novo Nordisk Investigational Site
    Austin, Texas 78758, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75230, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75231, United States
  • Novo Nordisk Investigational Site
    Round Rock, Texas 78681, United States
  • Novo Nordisk Investigational Site
    Murray, Utah 84123, United States
  • Novo Nordisk Investigational Site
    Ogden, Utah 84405, United States
  • Novo Nordisk Investigational Site
    Bennington, Vermont 05201, United States
  • Novo Nordisk Investigational Site
    Federal Way, Washington 98003, United States
  • Novo Nordisk Investigational Site
    Renton, Washington 98057, United States
  • Novo Nordisk Investigational Site
    Seattle, Washington 98195, United States
  • Novo Nordisk Investigational Site
    Graz, 8036, Austria
  • Novo Nordisk Investigational Site
    Wien, 1130, Austria
  • Novo Nordisk Investigational Site
    Aalst, 9300, Belgium
  • Novo Nordisk Investigational Site
    Bonheiden, 2820, Belgium
  • Novo Nordisk Investigational Site
    Boussu, 7300, Belgium
  • Novo Nordisk Investigational Site
    Brussels, 1090, Belgium
  • Novo Nordisk Investigational Site
    Bruxelles, 1200, Belgium
  • Novo Nordisk Investigational Site
    Edegem, 2650, Belgium
  • Novo Nordisk Investigational Site
    Kortrijk, 8500, Belgium
  • Novo Nordisk Investigational Site
    Leuven, 3000, Belgium
  • Novo Nordisk Investigational Site
    Mouscron, 7700, Belgium
  • Novo Nordisk Investigational Site
    Sint-Niklaas, 9100, Belgium
  • Novo Nordisk Investigational Site
    Blagoevgrad, 2700, Bulgaria
  • Novo Nordisk Investigational Site
    Pazardzhik, 4401, Bulgaria
  • Novo Nordisk Investigational Site
    Plovdiv, 4002, Bulgaria
  • Novo Nordisk Investigational Site
    Razgrad, 7200, Bulgaria
  • Novo Nordisk Investigational Site
    Sofia, 1431, Bulgaria
  • Novo Nordisk Investigational Site
    Calgary, Alberta T2V 4J2, Canada
  • Novo Nordisk Investigational Site
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Novo Nordisk Investigational Site
    Cornwall, Ontario K6H 4M4, Canada
  • Novo Nordisk Investigational Site
    Hamilton, Ontario L8N 3Z5, Canada
  • Novo Nordisk Investigational Site
    Mississauga, Ontario L5M 2V8, Canada
  • Novo Nordisk Investigational Site
    Thornhill, Ontario L4J 8L7, Canada
  • Novo Nordisk Investigational Site
    Laval, Quebec H7T 2P5, Canada
  • Novo Nordisk Investigational Site
    Montreal, Quebec H2X 0A9, Canada
  • Novo Nordisk Investigational Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • Novo Nordisk Investigational Site
    Hvidovre, 2650, Denmark
  • Novo Nordisk Investigational Site
    København, 2400, Denmark
  • Novo Nordisk Investigational Site
    Odense, 5000, Denmark
  • Novo Nordisk Investigational Site
    Århus C, 8000, Denmark
  • Novo Nordisk Investigational Site
    Helsinki, 00250, Finland
  • Novo Nordisk Investigational Site
    Joensuu, 80200, Finland
  • Novo Nordisk Investigational Site
    Jyväskylä, 40620, Finland
  • Novo Nordisk Investigational Site
    Oulu, FI-90220, Finland
  • Novo Nordisk Investigational Site
    Pori, 28500, Finland
  • Novo Nordisk Investigational Site
    Turku, FI-20520, Finland
  • Novo Nordisk Investigational Site
    LA ROCHELLE cedex, 17019, France
  • Novo Nordisk Investigational Site
    Le Creusot, 71200, France
  • Novo Nordisk Investigational Site
    MARSEILLE cedex 08, 13285, France
  • Novo Nordisk Investigational Site
    MONTPELLIER cedex 5, 34295, France
  • Novo Nordisk Investigational Site
    Paris, 75014, France
  • Novo Nordisk Investigational Site
    Pierre-Bénite, 69495, France
  • Novo Nordisk Investigational Site
    Reims, 51100, France
  • Novo Nordisk Investigational Site
    Strasbourg, 67098, France
  • Novo Nordisk Investigational Site
    TOULOUSE cedex, 31054, France
  • Novo Nordisk Investigational Site
    Trinité - La Martinique, 97235, France
  • Novo Nordisk Investigational Site
    Bergamo, 24127, Italy
  • Novo Nordisk Investigational Site
    Catanzaro, 88100, Italy
  • Novo Nordisk Investigational Site
    Firenze, 50141, Italy
  • Novo Nordisk Investigational Site
    Palermo, 90127, Italy
  • Novo Nordisk Investigational Site
    Roma, 00133, Italy
  • Novo Nordisk Investigational Site
    Roma, 00168, Italy
  • Novo Nordisk Investigational Site
    sesto san giovanni (MI), 20099, Italy

Showing the first 100 of 120 sites across 13 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Ahren B, Hirsch IB, Pieber TR, Mathieu C, Gomez-Peralta F, Hansen TK, Philotheou A, Birch S, Christiansen E, Jensen TJ, Buse JB; ADJUNCT TWO Investigators. Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial. Diabetes Care. 2016 Oct;39(10):1693-701. doi: 10.2337/dc16-0690. Epub 2016 Aug 4. PubMed 27493132 ↗
  • Hoogenhout M, Malcolm-Smith S. Theory of mind predicts severity level in autism. Autism. 2017 Feb;21(2):242-252. doi: 10.1177/1362361316636758. Epub 2016 Aug 19. PubMed 27493232 ↗
  • Dejgaard TF, von Scholten BJ, Christiansen E, Kreiner FF, Bardtrum L, von Herrath M, Mathieu C, Madsbad S; ADJUNCT ONE and ADJUNCT TWO Investigators. Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials. Diabetes Obes Metab. 2021 Dec;23(12):2752-2762. doi: 10.1111/dom.14532. Epub 2021 Sep 28. Erratum In: Diabetes Obes Metab. 2022 Nov;24(11):2280. doi: 10.1111/dom.14846. PubMed 34463425 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2016, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2014
First posted
Mar 28, 2014
Start
May 2014
Primary completionActual
Apr 2015
CompletionActual
Apr 2015
Results first posted
Jun 3, 2016
Last update
Feb 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02098395
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 28, 2014
Start date
May 2014
Primary completion
Apr 2015
Completion
Apr 2015
Results posted
Jun 3, 2016
Last update
Feb 9, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion